These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16502534)

  • 21. The DH register of cost-effectiveness studies: content and quality.
    Mason J; Drummond M
    Health Trends; 1995; 27(2):50-6. PubMed ID: 10153159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resource allocation to health authorities: the quest for an equitable formula in Britain and Sweden.
    Diderichsen F; Varde E; Whitehead M
    BMJ; 1997 Oct; 315(7112):875-8. PubMed ID: 9353512
    [No Abstract]   [Full Text] [Related]  

  • 23. How different are NHS systems across the UK since devolution?
    Hawkes N
    BMJ; 2013 May; 346():f3066. PubMed ID: 23674337
    [No Abstract]   [Full Text] [Related]  

  • 24. Review of NICE's recommendations, 1999-2005.
    Raftery J
    BMJ; 2006 May; 332(7552):1266-8. PubMed ID: 16735341
    [No Abstract]   [Full Text] [Related]  

  • 25. Value-Based Pharmaceutical Contracts: Value for Whom?
    Kannarkat JT; Good CB; Parekh N
    Value Health; 2020 Feb; 23(2):154-156. PubMed ID: 32113619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs.
    Husereau D; Dempster W; Blanchard A; Chambers J
    Value Health; 2014 Dec; 17(8):888-94. PubMed ID: 25498784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Playing safe on funding.
    O'Byrne J
    Nurs Stand; 1991 Jan 9-15; 5(15):23. PubMed ID: 1898855
    [No Abstract]   [Full Text] [Related]  

  • 29. Not so NICE. A proposal from the National Institute for Clinical Excellence to withdraw treatments for Alzheimer's disease from the NHS has left support groups reeling.
    Heath H
    Nurs Older People; 2005 Apr; 17(2):8. PubMed ID: 15835500
    [No Abstract]   [Full Text] [Related]  

  • 30. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
    Dranitsaris G; Ortega A; Lubbe MS; Truter I
    J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer's disease.
    Iliffe S
    CNS Drugs; 2007; 21(3):177-84. PubMed ID: 17338591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time to fix the price fix.
    Earl-Slater A
    Health Serv J; 1997 Nov; 107(5578):22-3. PubMed ID: 10174008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Price of medications: the actual system must be seen again].
    Mayencourt J
    Rev Med Suisse; 2016 Mar; 12(508):479. PubMed ID: 27089613
    [No Abstract]   [Full Text] [Related]  

  • 34. A NICE fallacy.
    Quigley M
    J Med Ethics; 2007 Aug; 33(8):465-6. PubMed ID: 17664304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increasing the Legitimacy of Tough Choices in Healthcare Reimbursement: Approach and Results of a Citizen Forum in The Netherlands.
    Bijlmakers L; Jansen M; Boer B; van Dijk W; Groenewoud S; Zwaap J; Helderman JK; van Exel J; Baltussen R
    Value Health; 2020 Jan; 23(1):32-38. PubMed ID: 31952671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Not a NICE fallacy: a reply to Dr Quigley.
    Claxton K; Culyer AJ
    J Med Ethics; 2008 Aug; 34(8):598-601. PubMed ID: 18667648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementing pharmacoeconomic guidelines in Latin America: lessons learned.
    Augustovski F; Melendez G; Lemgruber A; Drummond M
    Value Health; 2011; 14(5 Suppl 1):S3-7. PubMed ID: 21839895
    [No Abstract]   [Full Text] [Related]  

  • 38. Most drugs paid for by £1.27bn Cancer Drugs Fund had no "meaningful benefit".
    Cohen D
    BMJ; 2017 Apr; 357():j2097. PubMed ID: 28455308
    [No Abstract]   [Full Text] [Related]  

  • 39. QALYs and the integration of claims in health-care rationing.
    Anand P
    Health Care Anal; 1999; 7(3):239-53. PubMed ID: 10724553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients' views of explicit rationing: what are the implications for health service decision-making?
    Devlin N; Appleby J; Parkin D
    J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.